{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:26Z","timestamp":1793386466901,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Adolesc Psychiatry Ment Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aripiprazole is the most frequently recommended antipsychotic for the treatment of tics in children and adolescents with Tourette\u2019s disorder (TD). However, to date, a randomized controlled trial for aripiprazole oral solution has not been conducted despite being widely preferred by children. Therefore, we examined whether aripiprazole oral solution is effective for treating tics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients received a flexible dose of aripiprazole oral solution (1\u00a0mg\/mL, range: 2\u201320\u00a0mg) with a starting dose of 2\u00a0mg. The target dose for patients weighing\u2009&lt;\u200950\u00a0kg was 2, 5, and 10\u00a0mg\/day, and that for patients weighing\u2009\u2265\u200950\u00a0kg was 5, 10, 15, and 20\u00a0mg\/day. The primary efficacy endpoint was the mean change in the Yale Global Tic Severity Scale-total tic score (YGTSS-TTS) from baseline to week 8.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 121 patients enrolled, 59 patients (96.7%) in the aripiprazole group and 53 patients (88.3%) in the placebo group completed the study. The aripiprazole group showed significantly greater improvement in the YGTSS-TTS from baseline to week 8 than the placebo group (least squares mean difference [95% confidence interval (CI)] \u22125.5 [95% CI \u2212\u20098.4 to \u2212\u20092.6]). At week 8, the response rate (i.e., percentage of patients with a Tourette\u2019s Syndrome Clinical Global Impression-Improvement score of 1 or 2) of the aripiprazole group (86.4%) was significantly higher than that of the placebo group (56.6%; odds ratio: 3.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The incidence of treatment-emergent adverse events (TEAEs) reported in at least one patient was 86.9% in the aripiprazole group and 65.5% in the placebo group. All TEAEs were mild or moderate in severity. No serious adverse events or deaths occurred during the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that aripiprazole oral solution is an effective, well-tolerated, and safe treatment for children and adolescents with TD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT03487783. Registered 4 April 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13034-024-00764-6","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:03:00Z","timestamp":1721318580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette\u2019s disorder"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct03487783","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomichi","family":"Uki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"1 Pt 1","key":"764_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1542\/peds.102.1.14","volume":"102","author":"JF Leckman","year":"1998","unstructured":"Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, Kim YS, Peterson BS. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102(1 Pt 1):14\u20139.","journal-title":"Pediatrics"},{"issue":"4","key":"764_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2214.2009.00983.x","volume":"35","author":"D Cutler","year":"2009","unstructured":"Cutler D, Murphy T, Gilmour J, Heyman I. The quality of life of young people with Tourette syndrome. Child Care Health Dev. 2009;35(4):496\u2013504.","journal-title":"Child Care Health Dev"},{"issue":"19","key":"764_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.2010.607","volume":"303","author":"J Piacentini","year":"2010","unstructured":"Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, Ginsburg GS, Deckersbach T, Dziura J, Levi-Pearl S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929\u201337.","journal-title":"JAMA"},{"issue":"8","key":"764_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/archgenpsychiatry.2011.1528","volume":"69","author":"S Wilhelm","year":"2012","unstructured":"Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, Chang S, Liu H, Dziura J, Walkup JT, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69(8):795\u2013803.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"764_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/hup.2495","volume":"30","author":"M Farag","year":"2015","unstructured":"Farag M, Stern JS, Simmons H, Robertson MM. Serial pharmacological prescribing practices for tic management in Tourette syndrome. Human Psychopharmacol. 2015;30(6):435\u201341.","journal-title":"Human Psychopharmacol"},{"issue":"9","key":"764_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/02698811211032445","volume":"35","author":"FM Besag","year":"2021","unstructured":"Besag FM, Vasey MJ. Pharmacological treatment for Tourette syndrome in children and adults: what is the quality of the evidence?\u00a0A systematic review. J Psychopharmacol. 2021;35(9):1037\u201361.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"764_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1176\/ajp.136.3.317","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317\u201320.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"764_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","volume":"3","author":"L Scahill","year":"2006","unstructured":"Scahill L, Erenberg G, Berlin CM Jr., Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192\u2013206.","journal-title":"NeuroRx"},{"key":"764_CR9","first-page":"774","volume":"11","author":"ZS Liu","year":"2020","unstructured":"Liu ZS, Cui YH, Sun D, Lu Q, Jiang YW, Jiang L, Wang JQ, Luo R, Fang F, Zhou SZ, et al. Current status, diagnosis, and treatment recommendation for Tic disorders in China. Front Psychiatry. 2020;11:774.","journal-title":"Front Psychiatry"},{"issue":"1","key":"764_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"764_CR11","first-page":"250","volume":"18","author":"M Greenaway","year":"2009","unstructured":"Greenaway M. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18(3):250\u201360.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"3","key":"764_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40272-013-0024-6","volume":"15","author":"S Caccia","year":"2013","unstructured":"Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15(3):217\u201333.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"764_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pjnns.2017.10.015","volume":"52","author":"P Janik","year":"2018","unstructured":"Janik P, Szejko N. Aripiprazole in treatment of Gilles De La Tourette syndrome\u2014new therapeutic option. Neurol Neurochir Pol. 2018;52(1):84\u20137.","journal-title":"Neurol Neurochir Pol"},{"issue":"8","key":"764_CR14","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry. 2013;74(8):e772\u2013780.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"764_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R, Randomized. Double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771\u201381.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"764_CR16","doi-asserted-by":"publisher","DOI":"10.7916\/tohm.v0.645","author":"N Cothros","year":"2019","unstructured":"Cothros N, Martino D, McMorris C, Stewart D, Tehrani A, Pringsheim T. Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study. Tremor Other Hyperkinetic Mov. 2019. https:\/\/doi.org\/10.7916\/tohm.v0.645.","journal-title":"Tremor Other Hyperkinetic Mov"},{"issue":"6","key":"764_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.braindev.2019.02.003","volume":"41","author":"Y Hamamoto","year":"2019","unstructured":"Hamamoto Y, Fujio M, Nonaka M, Matsuda N, Kono T, Kano Y. Expert consensus on pharmacotherapy for tic disorders in Japan. Brain Dev. 2019;41(6):501\u20136.","journal-title":"Brain Dev"},{"issue":"22","key":"764_CR18","doi-asserted-by":"publisher","first-page":"e15816","DOI":"10.1097\/MD.0000000000015816","volume":"98","author":"C Yang","year":"2019","unstructured":"Yang C, Yi Q, Zhang L, Cui H, Mao J. Safety of aripiprazole for tics in children and adolescents: a systematic review and meta-analysis. Medicine. 2019;98(22):e15816.","journal-title":"Medicine"},{"issue":"3","key":"764_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","volume":"31","author":"V Roessner","year":"2022","unstructured":"Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425\u201341.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"764_CR20","unstructured":"Tokyo J. Otsuka Pharmaceutical Co., Ltd.: Abilify\u00ae (aripiprazole): Full Prescribing Information. 2020."},{"issue":"3","key":"764_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00787-010-0154-0","volume":"20","author":"HK Yoo","year":"2011","unstructured":"Yoo HK, Lee JS, Paik KW, Choi SH, Yoon SJ, Kim JE, Hong JP. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20(3):127\u201335.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"764_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pediatrneurol.2012.08.015","volume":"47","author":"R Rizzo","year":"2012","unstructured":"Rizzo R, Eddy CM, Cal\u00ed P, Gulisano M, Cavanna AE. Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol. 2012;47(6):419\u201322.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"764_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/JCP.0b013e31825ac2cb","volume":"32","author":"C Wenzel","year":"2012","unstructured":"Wenzel C, Kleimann A, Bokemeyer S, M\u00fcller-Vahl KR. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32(4):548\u201350.","journal-title":"J Clin Psychopharmacol"},{"key":"764_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/PHMT.S87121","volume":"7","author":"JH Cox","year":"2016","unstructured":"Cox JH, Seri S, Cavanna AE. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatr Health Med Ther. 2016;7:57\u201364.","journal-title":"Pediatr Health Med Ther"},{"issue":"19","key":"764_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, M\u00fcller-Vahl K, Woods DW, Robinson M, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907\u201315.","journal-title":"Neurology"},{"issue":"5","key":"764_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/pharmaceutics13050730","volume":"13","author":"E Alessandrini","year":"2021","unstructured":"Alessandrini E, Brako F, Scarpa M, Lupo M, Bonifazi D, Pignataro V, Cavallo M, Cullufe O, Enache C, Nafria B, et al. Children\u2019s preferences for oral dosage forms and their involvement in formulation research via EPTRI (European paediatric translational research infrastructure). Pharmaceutics. 2021;13(5):730.","journal-title":"Pharmaceutics"},{"issue":"4","key":"764_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF Leckman","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28(4):566\u201373.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"764_CR28","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1212\/WNL.38.12.1902-a","volume":"38","author":"J Leckman","year":"1988","unstructured":"Leckman J, Sweet RD. Tourette\u2019s syndrome and Tic disorders: clinical understanding and treatment. Neurology. 1988;38(12):1902\u20131902.","journal-title":"Neurology"},{"issue":"2","key":"764_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cct.2013.08.012","volume":"36","author":"S Jeon","year":"2013","unstructured":"Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J, Wilhelm S, Katsovich L, McGuire JF, Dziura J, Scahill L. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials. 2013;36(2):414\u201320.","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"764_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10578-013-0427-1","volume":"45","author":"A Ghanizadeh","year":"2014","unstructured":"Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45(5):596\u2013603.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"3","key":"764_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/070674371205700302","volume":"57","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry Revue Canadienne de Psychiatrie. 2012;57(3):133\u201343.","journal-title":"Can J Psychiatry Revue Canadienne de Psychiatrie"},{"issue":"8","key":"764_CR32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/0006-3223(92)90311-M","volume":"31","author":"RD Todd","year":"1992","unstructured":"Todd RD. Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol Psychiatry. 1992;31(8):794\u2013807.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"764_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","volume":"165","author":"RL Findling","year":"2008","unstructured":"Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432\u201341.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"764_CR34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","volume":"70","author":"RL Findling","year":"2009","unstructured":"Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441\u201351.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"764_CR35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"764_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bdi.12042","volume":"15","author":"RL Findling","year":"2013","unstructured":"Findling RL, Correll CU, Nyilas M, Forbes RA, McQuade RD, Jin N, Ivanova S, Mankoski R, Carson WH, Carlson GA. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013;15(2):138\u201349.","journal-title":"Bipolar Disord"}],"container-title":["Child and Adolescent Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-024-00764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-024-00764-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-024-00764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:05:31Z","timestamp":1721318731000},"score":1,"resource":{"primary":{"URL":"https:\/\/capmh.biomedcentral.com\/articles\/10.1186\/s13034-024-00764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1186\/s13034-024-00764-6","relation":{},"ISSN":["1753-2000"],"issn-type":[{"value":"1753-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. All procedures were approved by the ethics committee of each trial site (ClinicalTrials.gov Identifier: NCT03487783). This study was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice and applicable local laws and requirements. The study procedures were conducted in keeping with the standards set out in the Announcement of Helsinki and the Laboratory Guidelines of Research in China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}